StreetInsider.com News Articles

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

NEW YORK CITY, NY / ACCESS Newswire / October 24, 2026 / Where capital flows, how disease is treated, how entertainment reaches the screen and how the world is powered are all being rewritten at once. Tonight, New to The Street brings four companies working at each of those frontiers to a global business audience as Show #777 premieres at 6:30 p.m. ET on Bloomberg Television as sponsored programming, with distribution across the United States, Latin America, the Middle East and North Africa (MENA) and Southeast Asia.

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

Sat, 24 Oct 2026 10:30:00 -0400

Hosted by Jane King and opening

BioVie shares Phase 2 bezisterim data for Parkinson's disease

Tue, 20 Oct 2026 08:07:30 -0400

BioVie Inc. (NASDAQ: BIVI) presented results from its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim in early Parkinson's disease patients at the 151st Annual Meeting of the American Neurological Association, held October 17–20, 2026, in San Diego. The study's abstract was published in Annals of Neurology.

The 57-patient randomized, double-blind, placebo-controlled trial administered bezisterim or placebo for 12 weeks. Patients with above-median platelet counts at baseline — above 230 × 10⁹/L, used as a marker of elevated systemic inflammation — showed statistically significant improvements compared to placebo. In this prespecified subgroup, bezisterim-treated patients showed improvement in MDS-UPDRS Part I non-motor scores

BioVie shares Phase 2 bezisterim data for Parkinson's disease

Tue, 20 Oct 2026 08:07:30 -0400

BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting

Tue, 20 Oct 2026 08:00:00 -0400

Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo.

CARSON CITY, Nev., Oct. 20, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of results from the Phase 2 SUNRISE-PD clinical trial evaluating bezisterim in early Parkinson’s patients at the 151st Annual Meeting of the American Neurological Association (ANA), held October 17–20, 2026, in San Diego, California. The study’s abstract was published in Annals of Neurology (Vol.

BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting

Tue, 20 Oct 2026 08:00:00 -0400

Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo.

BioVie shares Phase 2 bezisterim data for Long COVID treatment

Mon, 19 Oct 2026 08:01:40 -0400

BioVie Inc. (NASDAQ: BIVI) presented results from its Phase 2 ADDRESS-LC trial evaluating bezisterim (NE3107) in Long COVID patients at the 151st Annual Meeting of the American Neurological Association, held Oct. 17–20, 2026, in San Diego.

The randomized, double-blind, placebo-controlled trial enrolled 203 patients who received bezisterim or placebo for 12 weeks. The study assessed 22 clinical outcome measures, with no single endpoint designated as primary. In the overall intent-to-treat population, bezisterim did not achieve statistical significance on any endpoint.

Statistically significant results were observed in pre-specified subgroups of patients with greater baseline symptom burden. Among the most fatigued patients at baseline,

BioVie shares Phase 2 bezisterim data for Long COVID treatment

Mon, 19 Oct 2026 08:01:40 -0400

Statistically significant results were observed in pre-specified subgroups of patients with greater baseline symptom burden. Among the most fatigued patients at baseline,

BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting

Mon, 19 Oct 2026 08:00:00 -0400

CARSON CITY, Nev., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of results from the Phase 2 ADDRESS-LC study (NCT06847191) evaluating bezisterim (NE3107) in patients with Long COVID at the 151st Annual Meeting of the American Neurological Association (ANA), held October 17–20, 2026, in San Diego, California. The study’s abstract was published in Annals of Neurology (Vol. 100, pp. S4–S375, https://doi.org/10.1002%2Fana.78378), in conjunction with the meeting.

The poster,